Gilead Sciences Inc

Gilead Sciences Inc. is set to report its Q4 2024 earnings on October 30, with analysts expecting a modest EPS gain and revenue decline, amidst a competitive landscape and regulatory headwinds.

Gilead Sciences’ Phase III ASCENT-03 trial has shown that its cancer treatment Trodelvy significantly improves outcomes for patients with metastatic triple-negative breast cancer, meeting its primary endpoint and paving the way for potential FDA app…

Gilead Sciences’ stock price declined 1% after CVS excluded its new HIV medication Yeztugo from its formulary, but the company has since made a bold move to expand its oncology pipeline through a $350 million acquisition.

Gilead Sciences exceeded expectations in its strong second quarter, driven by the success of its HIV medication Biktarvy, and has revised its 2025 guidance upwards.

The biotech sector is experiencing a surge in optimism, with Gilead Sciences and other key players seeing significant gains in stock price due to expectations of a US interest rate cut.

Gilead Sciences’ stock price surged 2.9% after the European Medicines Agency recommended its HIV prevention treatment lenacapavir for approval in the EU.

Gilead Sciences’ stock has seen a surge in value due to unusual options trading and a deal to offer an HIV vaccine to low-income nations, but the company is also facing investigations into potential securities fraud.

Gilead Sciences is at the center of a maelstrom of conflicting news that could either catapult its stock to new heights or send it plummeting into a financial abyss.

Gilead Sciences, a biopharmaceutical company, has seen its stock price surge to a 52-week high due to increased call options trading and promising results from its HIV prevention treatment, lenacapavir.

Gilead Sciences’ stock price has surged following a US Supreme Court ruling that requires health insurers to cover preventive care services, including HIV risk reduction and cancer screenings.